Loading company…
Satellite Biosciences develops cellular therapies to address critical organ dysfunction, including liver conditions.
Satellite Biosciences develops therapies using living cells, including its SAT Platform to support the function and engraftment of mature hepatocyte cells. Founded in 2019, the company is based in Cambridge, US. In February 2022, it raised USD 82.5 mn in Series A funding from aMoon, Polaris Partners, and Lightspeed Venture Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in